Profluent
Profluent develops deep generative models to design and validate novel, functional proteins to revolutionize biomedicine.
Challenge
How do you launch an AI-first protein design company developing deep generative models to design and validate novel, functional proteins to revolutionize biomedicine?
Approach
Profluent was founded on the principle of AI as an interpreter to decode the language of life and transcend the limits of traditional protein engineering. Previous approaches required inefficient searches within nature or brute-force mutagenesis, greatly hampering the resulting probability of success.
In contrast, Profluent’s models can rapidly access an immense combinatorial space to optimize across multiple functional attributes, enabling a paradigm shift from accidental discovery to intentional design.
By first applying its platform to gene editing, the company showcases AI as the ideal interface for engineering complex biological systems. The versatility of the platform allows for AI to precisely tune existing CRISPR scaffolds or create novel editing systems from scratch, with the ultimate goal of crafting the right tool for each patient..
We partnered with Profluent to plan and execute their long term PR strategy including an $35M additional funding announcement, launch of OpenCRISPR – the world’s first AI-created and open-source gene editor – and ProseLM, a unique method of generating proteins with atomic-level control.
Impact
Thermal’s media approach has helped establish Profluent’s reputation as the leading AI-first protein design company, harnessing AI to enable researchers to reimagine and build gene editing systems from the ground up, which would be impossible with conventional protein engineering methods.
This positioning and strategic rollout earned Profluent more than 45 featured articles including coverage in The New York Times, BBC News, Endpoints, GEN, TechCrunch, STAT News, The Scientist, Fortune, The Wall Street Journal, etc. that resulted in more than 1.5 millions views and an audience of 849 million.
We continue to proudly support Profluent’s work and spotlight their pioneering approach to create bespoke proteins for breakthrough medicines.
OpenCRISPR-1
world’s first AI-created open-source gene editor
ProseLM
atomistic level control
“We are moving biology from being constrained by what can be discovered in nature to being able to design precisely according to our needs via AI. The science is real and the time is now to proactively create breakthrough medicines that can transform society.”
Ali Madani – Co-founder and CEO of Profluent
